Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

GNI/Shanghai Genomics to Start China Clinical Trials of Liver Drug

publication date: Nov 21, 2007
GNI Ltd received an Investigational New Drug approval of F351, its novel treatment for liver fibrosis/cirrhosis, a currently unmet need. Shanghai Genomics, the China-based affiliate of GNI, is preparing for a Phase I clinical trial of F351. Two weeks ago, Shanghai Genomics was granted a patent in China for the drug. The business offices for GNI are in Tokyo, but R&D is carried out in Fukuoka (Japan), Cambridge (UK) and China. It has an intellectual property office in San Jose, California, and its clinical trial operations are carried out through Shanghai Genomics, located in the Zhangjiang Hi-Tech Park of Shanghai. More details...

Stock Symbol: (TOKYO: 2160)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital